Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.

Nicholas David James; Lazaros Andronis; Ilias Goranitis; Sarah Pirrie; Ann Pope; Darren Barton; Adam Daunton; Duncan McLaren; Joe M. O'Sullivan; Chris Parker; John Staffurth; Andrew Stanley; James Wylie; Sharon Beesley; Alison J. Birtle; Janet Elizabeth Brown; Prabir R. Chakraborti; John Martin Russell; Lucinda Billingham

doi:10.1200/jco.2015.33.15_suppl.e16108

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.

Nicholas David James, Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, Ann Pope, Darren Barton, Adam Daunton, Duncan McLaren, Joe M. O'Sullivan, Chris Parker, John Staffurth, Andrew Stanley, James Wylie, Sharon Beesley, Alison J. Birtle, Janet Elizabeth Brown, Prabir R. Chakraborti, John Martin Russell, Lucinda Billingham

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	33
Issue number	15
DOIs	https://doi.org/10.1200/jco.2015.33.15_suppl.e16108
Publication status	Published - 20 May 2015
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer - Chicago, Israel Duration: 29 May 2015 → 2 Jun 2015

Access to Document

10.1200/jco.2015.33.15_suppl.e16108

Cite this

James, N. D., Andronis, L., Goranitis, I., Pirrie, S., Pope, A., Barton, D., Daunton, A., McLaren, D., O'Sullivan, J. M., Parker, C., Staffurth, J., Stanley, A., Wylie, J., Beesley, S., Birtle, A. J., Brown, J. E., Chakraborti, P. R., Russell, J. M., & Billingham, L. (2015). Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE. Journal of Clinical Oncology, 33(15). https://doi.org/10.1200/jco.2015.33.15_suppl.e16108

@article{29152e7542e24e6d8f672666d01790f4,

title = "Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.",

author = "James, {Nicholas David} and Lazaros Andronis and Ilias Goranitis and Sarah Pirrie and Ann Pope and Darren Barton and Adam Daunton and Duncan McLaren and O'Sullivan, {Joe M.} and Chris Parker and John Staffurth and Andrew Stanley and James Wylie and Sharon Beesley and Birtle, {Alison J.} and Brown, {Janet Elizabeth} and Chakraborti, {Prabir R.} and Russell, {John Martin} and Lucinda Billingham",

year = "2015",

month = may,

day = "20",

doi = "10.1200/jco.2015.33.15_suppl.e16108",

language = "English",

volume = "33",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "15",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer ; Conference date: 29-05-2015 Through 02-06-2015",

}

James, ND, Andronis, L, Goranitis, I, Pirrie, S, Pope, A, Barton, D, Daunton, A, McLaren, D, O'Sullivan, JM, Parker, C, Staffurth, J, Stanley, A, Wylie, J, Beesley, S, Birtle, AJ, Brown, JE, Chakraborti, PR, Russell, JM & Billingham, L 2015, 'Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.', Journal of Clinical Oncology, vol. 33, no. 15. https://doi.org/10.1200/jco.2015.33.15_suppl.e16108

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE. / James, Nicholas David; Andronis, Lazaros; Goranitis, Ilias et al.
In: Journal of Clinical Oncology, Vol. 33, No. 15, 20.05.2015.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.

AU - James, Nicholas David

AU - Andronis, Lazaros

AU - Goranitis, Ilias

AU - Pirrie, Sarah

AU - Pope, Ann

AU - Barton, Darren

AU - Daunton, Adam

AU - McLaren, Duncan

AU - O'Sullivan, Joe M.

AU - Parker, Chris

AU - Staffurth, John

AU - Stanley, Andrew

AU - Wylie, James

AU - Beesley, Sharon

AU - Birtle, Alison J.

AU - Brown, Janet Elizabeth

AU - Chakraborti, Prabir R.

AU - Russell, John Martin

AU - Billingham, Lucinda

PY - 2015/5/20

Y1 - 2015/5/20

U2 - 10.1200/jco.2015.33.15_suppl.e16108

DO - 10.1200/jco.2015.33.15_suppl.e16108

M3 - Meeting abstract

SN - 0732-183X

VL - 33

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer

Y2 - 29 May 2015 through 2 June 2015

ER -